23:09 , Aug 28, 2017 |  BC Week In Review  |  Clinical News

FDA approves Ironwood's Duzallo for gout

Ironwood Pharmaceuticals Inc. (NASDAQ:IRWD) said FDA approved Duzallo lesinurad/allopurinol to treat hyperuricemia associated with gout in patients who have not achieved target serum uric acid levels with allopurinol alone. The company expects to launch the...
16:26 , Apr 13, 2017 |  BC Innovations  |  Translation in Brief

Culprit: yeast

Turning an eye to the often ignored non-bacterial members of the microbiome, University of Utah researchers have shown the yeast species...
07:00 , May 28, 2007 |  BC Week In Review  |  Company News

Bioniche Pharma Group Ltd., Nabi deal

Bioniche's Bioniche Teoranta unit completed its previously announced acquisition of NABI's Aloprim IV allopurinol for $3.7 million, including $1.3 million up front, $1.4 million at year end and $1 million at the end of 2008...
07:00 , Apr 23, 2007 |  BC Week In Review  |  Company News

Bioniche Pharma Group Ltd., Nabi deal

NABI agreed to sell Aloprim IV allopurinol to Bioniche’s Bioniche Teoranta unit for $3.7 million. The move is part of NABI’s plan to reorganize into two business units and partner or sell certain of its...
07:00 , Mar 19, 2007 |  BC Week In Review  |  Company News

Nabi renal, infectious, neurology news

The reorganization follows a strategic alternatives process that began last year (see BioCentury, Oct. 2, 2006). NABI hopes to complete the process by year end. At Dec. 31, 2006, the company had $86.2 million in...
08:00 , Nov 7, 2005 |  BioCentury  |  Product Development

Nabi chronicles

Nabi chronicles...
07:00 , Jul 5, 2004 |  BC Week In Review  |  Company News

DSM Biologics N.V., Nabi Biopharmaceuticals Inc. deal

NABI exercised its option to acquire exclusive worldwide distribution rights from DSM to Aloprim intravenous allopurinol. The compound is approved to control elevated uric acid levels in patients with leukemia, lymphoma and solid tumors who...
07:00 , Jun 21, 1999 |  BC Week In Review  |  Company News

Catalytica, Nabi deal

NABI acquired exclusive U.S. distribution rights to Aloprim intravenous allopurinol to control elevated uric acid levels in patients with leukemia, lymphoma and solid tumors. NABI, which will launch Aloprim immediately, will share profits with CTAL....